Mint Venture Partners, a South Korean bio-healthcare-focused venture studio, said it fully recovered the principal and benchmark returns of its first fund after all three major portfolio companies listed on KOSDAQ within five years. Organoid Science listed in May 2025, AimedBio, an antibody-drug conjugate developer, in December 2025, and Mezoo, a wearable electrocardiogram monitoring company, in March 2026. Recovery multiples were 23.1 times invested capital for AimedBio, 9.1 times for Mezoo and 1.47 times for Organoid Science. The fund, officially named Mint Global Biotech Private Equity Limited Partnership, was formed in 2021 as Mint Venture Partners' first blind-pool fund. The firm now has investments in 27 companies, is pursuing two new funds and plans to expand into drug development, diagnostics, precision medicine and AI healthcare while building companies directly and developing strategic partnerships.